To determine whether telaglenastat could suppress mTOR pathway activity in RCC, we measured phosphorylation of S6 and 4E-BP1, markers of mTOR activation, across 6 ccRCC cell lines. Here, MTOR is linked to nonpapillary renal cell carcinoma.